Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications
Journal of the American College of Cardiology · 2023-11 · 82 (19) · 1809-1823
DOI: 10.1016/j.jacc.2023.08.045 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2023-11. Verfasst von David E Kandzari und 30 weiteren Autor:innen. Beteiligte Einrichtung: Piedmont Heart Institute, Atlanta, Georgia, USA. Electronic address: david.kandzari@piedmont.org. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension. Die Arbeit wurde bisher 123-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: British Heart Foundation, Medtronic Inc.
Abstract (Originalsprache)
BACKGROUND: Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled hypertension in the absence of antihypertensive medications. OBJECTIVES: This trial assessed the safety and efficacy of RDN in the presence of antihypertensive medications. METHODS: SPYRAL HTN-ON MED is a prospective, randomized, sham-controlled, patient- and assessor-blinded trial enrolling patients from 56 clinical centers worldwide. Patients were prescribed 1 to 3 antihypertensive medications. Patients were randomized to radiofrequency RDN or sham control procedure. The primary efficacy endpoint was the baseline-adjusted change in mean 24-hour ambulatory systolic BP at 6 months between groups using a Bayesian trial design and analysis. RESULTS: The treatment difference in the mean 24-hour ambulatory systolic BP from baseline to 6 months between the RDN group (n = 206; -6.5 ± 10.7 mm Hg) and sham control group (n = 131; -4.5 ± 10.3 mm Hg) was -1.9 mm Hg (95% CI: -4.4 to 0.5 mm Hg; P = 0.12). There was no significant difference between groups in the primary efficacy analysis with a posterior probability of superiority of 0.51 (Bayesian treatment difference: -0.03 mm Hg [95% CI: -2.82 to 2.77 mm Hg]). However, there were changes and increases in medication intensity among sham control patients. RDN was associated with a reduction in office systolic BP compared with sham control at 6 months (adjusted treatment difference: -4.9 mm Hg; P = 0.0015). Night-time BP reductions and win ratio analysis also favored RDN. There was 1 adverse safety event among 253 assessed patients. CONCLUSIONS: There was no significant difference between groups in the primary analysis. However, multiple secondary endpoint analyses favored RDN over sham control. (SPYRAL HTN-ON MED Study [Global Clinical Study of Renal Denervation With the Symplicity Spyral Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications]; NCT02439775).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Piedmont Heart Institute, Atlanta, Georgia, USA. Electronic address: david.kandzari@piedmont.org.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Departmnet of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
- Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany.
- SUNY Downstate College of Medicine, New York, New York, USA.
- University Hospital Erlangen, Erlangen, Germany.
Förderung
- British Heart Foundation
- Medtronic Inc
Zitieren
APA
Kandzari, D. E., Townsend, R. R., Kario, K., Mahfoud, F., Weber, M. A., Schmieder, R. E., Pocock, S., Tsioufis, K., Konstantinidis, D., Choi, J., East, C., Lauder, L., Cohen, D. L., Kobayashi, T., Schmid, A., Lee, D. P., Ma, A., Weil, J., Agdirlioglu, T., …, & SPYRAL HTN-ON MED Investigators (2023). Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. Journal of the American College of Cardiology, 82(19), 1809-1823. https://doi.org/10.1016/j.jacc.2023.08.045
Vancouver
Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. Journal of the American College of Cardiology. 2023;82(19):1809-1823. doi:10.1016/j.jacc.2023.08.045
BibTeX
@article{Kandzari2023,
author = {Kandzari, David E and Townsend, Raymond R and Kario, Kazuomi and Mahfoud, Felix and Weber, Michael A and Schmieder, Roland E and Pocock, Stuart and Tsioufis, Konstantinos and Konstantinidis, Dimitrios and Choi, James and East, Cara and Lauder, Lucas and Cohen, Debbie L and Kobayashi, Taisei and Schmid, Axel and Lee, David P and Ma, Adrian and Weil, Joachim and Agdirlioglu, Tolga and Schlaich, Markus P and Shetty, Sharad and Devireddy, Chandan M and Lea, Janice and Aoki, Jiro and Sharp, Andrew S P and Anderson, Richard and Fahy, Martin and DeBruin, Vanessa and Brar, Sandeep and Böhm, Michael and SPYRAL HTN-ON MED Investigators, SPYRAL HTN-ON MED Investigators},
title = {Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications},
journal = {Journal of the American College of Cardiology},
year = {2023},
volume = {82},
number = {19},
pages = {1809--1823},
doi = {10.1016/j.jacc.2023.08.045}
}
EUVIMED